ClinicalTrials.gg
TerminatedNCT06881251DUPLEX-ADUpdated Jul 31, 2026

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

A Phase 2 interventional study of Dupilumab and JNJ-95475939 in Dermatitis, Atopic, sponsored by Janssen Research & Development, LLC. Terminated at 71 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Why this study was terminated
Terminated: futility criteria met at interim efficacy analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Dermatitis, Atopic by Johnson & Johnson — none open to participants now, 1 under way, none of them phase 3. Dermatitis, Atopic · Johnson & Johnson.

Enrollment
Largest of 25
256 · median 74
Started
2025
the only one that year
Phase 2
10 of 25
none open now
Registered
24th of 25
by date

Among the 25 studies in Dermatitis, Atopic by Johnson & Johnson, this one has the largest enrollment, is the only one that started in 2025, is one of 10 in phase 2, and was the 24th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 25 studies in Dermatitis, Atopic by Johnson & Johnson is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Dermatitis, Atopic by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic Atopic Dermatitis (AD), according to American Academy of Dermatology Consensus Criteria with onset of symptoms at least 1 year prior to the screening visit
  • Eczema Area and Severity Index (EASI) score greater than and equal to (>=) 16 at the screening and baseline visits
  • Validated investigator global assessment for AD (vIGA-AD) score >= 3 at the screening and baseline visits
  • >= 10% body surface area (BSA) of AD involvement at the screening and baseline visits
  • Baseline Peak Pruritus Numeric(al) Rating Scale (PP-NRS) average score of >=4
  • Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, or inadequate response to systemic therapies (within 12 months before screening)
  • Participant has applied a moisturizer at least once daily for at least 7 days before the baseline visit

Exclusion criteria

Exclusion criteria:

  • Experienced primary efficacy failure (no response within 16 weeks) or an adverse event (AE) requiring discontinuation related to agents (eg, severe ocular surface disease, dupilumab-associated facial redness) inhibiting IL-4Rα, IL-4, and/or IL-13 signaling (eg, dupilumab, lebrikizumab, or tralokinumab)
  • Participant is pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study
  • Active skin disease other than AD including eczema herpeticum, molluscum contagiosum, impetigo, psoriasis or has any other ongoing significant skin condition including skin infections, that, according to the investigator, could interfere with efficacy assessments
  • Current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Recent case of eczema herpeticum, herpes zoster within 8 weeks before screening, or history of recurrent eczema herpeticum
  • History of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (eg, untreated latent tuberculosis), recurrent urinary tract infection, fungal infection, mycobacterial infection, or open, draining, or infected skin wounds, or ulcers.
  • Diagnosed active parasitic infection or at high risk of parasitic infection, unless treated with antihelminth therapy prior to randomization
  • Had major surgery (eg, requiring general anesthesia and hospitalization), within 8 weeks before screening, or will not have fully recovered from surgery, or has such surgery planned during the time the participant is expected to participate in the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
256 participants (actual)

Study arms

  • Active comparator
    Group A: Dupilumab

    Participants will receive Dupilumab dose regimen 1 subcutaneously through Week 22.

    Drug: Dupilumab

  • Experimental
    Group B: JNJ-95475939

    Participants will receive JNJ-95475939 dose regimen 1 subcutaneously through Week 22.

    Drug: JNJ-95475939

  • Experimental
    Group C: JNJ-95475939

    Participants will receive JNJ-95475939 dose regimen 2 subcutaneously through Week 22.

    Drug: JNJ-95475939

  • Experimental
    Group D: JNJ-95475939

    Participants will receive JNJ-95475939 dose regimen 3 subcutaneously through Week 22.

    Drug: JNJ-95475939

  • Placebo comparator
    Group E: Placebo

    Participants will receive matching placebo subcutaneously through Week 10, then switch to receive JNJ-95475939 dose regimen 1 subcutaneously between Week 12 and Week 22.

    Drug: JNJ-95475939 · Drug: Placebo

Interventions

  • Dupilumab will be administered subcutaneously.

  • DrugJNJ-95475939

    JNJ-95475939 will be administered subcutaneously.

  • DrugPlacebo

    Placebo will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Eczema Area and Severity Index (EASI) 75 Response at Week 12

    EASI-75 response is defined as at least 75 percent (%) improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants With EASI-90 Response at Week 12

    EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 12

  2. Percentage of Participants With EASI-100 Response at Week 12

    EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 12

  3. Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 and a Reduction From Baseline of Greater Than Equal to (>=) 2 Points at Week 12

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 12

  4. Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 12

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 12

  5. Percent Change From Baseline in the EASI Total Score at Week 12

    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 12

  6. Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 12

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 12

  7. Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 12

    The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 12

  8. Percent Change from Baseline in Skin Pain NRS Score at Week 12

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 12

  9. Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 12

    The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times.

    Time frame: Baseline, Week 12

  10. Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 12

    The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: From Baseline through Week 12

  11. Percentage of Participants with EASI-75 Response at Week 16

    EASI-75 response is defined as at least 75% improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 16

  12. Percentage of Participants with EASI-90 Response at Week 16

    EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 16

  13. Percentage of Participants with EASI-100 Response at Week 16

    EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Week 16

  14. Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 16

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 16

  15. Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 16

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 16

  16. Percent Change from Baseline in the EASI Total Score at Week 16

    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 16

  17. Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 16

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 16

  18. Percent Change from Baseline in PP-NRS Score at Week 16

    The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 16

  19. Percent Change from Baseline in Skin Pain NRS Score at Week 16

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 16

  20. Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 16

    The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times.

    Time frame: Baseline, Week 16

  21. Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 24

    The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: From Baseline Through Week 24

  22. Percentage of Participants with EASI-75 Response at Week 24

    EASI-75 response is defined as at least 75% improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 24

  23. Percentage of Participants with EASI-90 Response at Week 24

    EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Week 24

  24. Percentage of Participants with EASI-100 Response at Week 24

    EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Week 24

  25. Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 24

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 24

  26. Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 24

    vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD.

    Time frame: Baseline, Week 24

  27. Percent Change from Baseline in the EASI Total Score at Week 24

    The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD.

    Time frame: Baseline, Week 24

  28. Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain NRS Score From Baseline to Week 24

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 24

  29. Percent Change From Baseline in PP-NRS Score at Week 24

    The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 24

  30. Percent Change from Baseline in Skin Pain NRS Score at Week 24

    The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity.

    Time frame: Baseline, Week 24

  31. Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 24

    The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times.

    Time frame: Baseline, Week 24

  32. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Participants with AEs and SAEs will be reported. An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly.

    Time frame: From Baseline up to Week 36

07

Study locations

71 sites
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • University of California Los Angeles - Division of Dermatology
    Los Angeles, California 90024, United States
  • Hamilton Research LLC
    Alpharetta, Georgia 30022, United States
  • DeNova Research
    Chicago, Illinois 60602, United States
  • Dawes Fretzin Clinical Research Group LLC
    Indianapolis, Indiana 46250, United States
  • Indiana Clinical Trial Center
    Plainfield, Indiana 46168, United States
  • Red River Research Partners LLC
    Fargo, North Dakota 58103, United States
  • Optima Research
    Boardman, Ohio 44512, United States
  • Oregon Medical Research Center
    Portland, Oregon 97201, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Frontier Derm Partners CRO, LLC
    Mill Creek, Washington 98012, United States
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • INAER - Investigacion en Alergias y Enfermedades Respiratorias
    Buenos Aires, C1425, Argentina
  • Instituto de Neumonologia y Dermatologia
    Buenos Aires, C1425, Argentina
  • Derma Internacional S A
    Buenos Aires, C1426, Argentina
  • Ceti - Centro de Estudos Em Terapias Inovadoras
    Curitiba, 80.030-110, Brazil
  • Hospital De Clinicas De Porto Alegre
    Porto Alegre, 90035 903, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP
    Ribeirão Preto, 14048 900, Brazil
  • Instituto Brasil de Pesquisa Clinica
    Rio de Janeiro, 20241 180, Brazil
  • Fundacao do ABC Centro Universitario FMABC
    Santo André, 09060 870, Brazil
  • BR TRIALS Ensaios Clinicos e Consultoria Ltda
    São Paulo, 01236030, Brazil
  • Dermatology Research Institute Inc
    Calgary, Alberta T2J 7E1, Canada
  • Dr. Chih ho Hong Medical
    Surrey, British Columbia V3R 6A7, Canada
  • Karma Clinical Trials Inc.
    St. John's, Newfoundland and Labrador A1A 4Y3, Canada
  • SimcoDerm Medical and Surgical Dermatology Centre
    Barrie, Ontario L4M 7G1, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2X 2V1, Canada
  • Centre De Recherche Dermatologique Du Quebec Metropolitain
    Québec, Quebec G1V 4X7, Canada
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Charite - Universitaetsmedizin Berlin (CCM)
    Berlin, 10117, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Studienzentrum an der Hase GbR
    Bramsche, 49565, Germany
  • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum Dusseldorf
    Düsseldorf, 40225, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt, 60596, Germany
  • Eurofins bioskin GmbH
    Hamburg, 20095, Germany
  • Studienzentrum Dr Schwarz Germany
    Langenau, 89129, Germany
  • Fukuoka University Hospital
    Fukuoka, 814-0180, Japan
  • Osaka Habikino Medical Center
    Habikino, 583 8588, Japan
  • Teikyo University Hospital
    Itabashi Ku, 173 8606, Japan
  • Kume Clinic
    Sakai, 593 8324, Japan
  • Sapporo Skin Clinic
    Sapporo, 060 0063, Japan
  • Jitaikai Tachikawa dermatology clinic
    Tachikawa, 190 0023, Japan
  • Shirasaki Dermatology Clinic
    Takaoka Shi, 933-0871, Japan
  • Mie University Hospital
    Tsu, 514-8507, Japan
  • Queens Square Medical Facilities
    Yokohama, 220 6208, Japan
  • Nomura Dermatology Clinic
    Yokohama, 221 0825, Japan
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Care Clinic
    Katowice, 40 568, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, 40-611, Poland
  • Centrum Medyczne All Med
    Krakow, 30 033, Poland
  • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
    Krakow, 30-002, Poland
  • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
    Lodz, 90-338, Poland
  • Therapia Nova
    Warsaw, 01 595, Poland
  • Klinika Ambroziak Dermatologia
    Warsaw, 02 953, Poland
  • Royalderm Agnieszka Nawrocka
    Warsaw, 02962, Poland
  • WroMedica I Bielicka A Strzalkowska s c
    Wroclaw, 51 685, Poland
  • Hosp. Gral. Univ. Dr. Balmis
    Alicante, 03010, Spain
  • Hosp. Univ. San Cecilio
    Granada, 18016, Spain
  • Hosp. Univ. de Bellvitge
    LHospitalet de Llobregat, 08907, Spain
  • Grupo Dermatologico Y Estetico Pedro Jaen
    Madrid, 28002, Spain
  • Hosp. Univ. de La Princesa
    Madrid, 28006, Spain
  • Hosp. de Manises
    Manises, 46940, Spain
  • Hosp. Clinico Univ. de Santiago
    Santiago de Compostela, 15706, Spain
  • The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
    Kings Lynn, PE30 4ET, United Kingdom
  • Royal London Hospital
    London, E1 1BB, United Kingdom
  • Northwick Park Hospital
    London, HA13UJ, United Kingdom
  • Guys and St Thomas NHS Foundation Trust
    London, SE1 9RT, United Kingdom
  • Salford Royal Hospital
    Salford, M6 8HD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Mar 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 18, 2025
StartActual
Feb 26, 2025
Primary completionActual
Mar 26, 2026
CompletionActual
Apr 7, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06881251
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Feb 26, 2025
Primary completion
Mar 26, 2026
Completion
Apr 7, 2026
Last update
Jul 31, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion